Marvin Visit 1: Prevent the Event: Defining the Risk of Atherothrombosis

Title:

Marvin Visit 1: Prevent the Event: Defining the Risk of Atherothrombosis
Topic: Cardiology
Relevant Terms: Atherothrombosis, Cardiovascular Diseases, CVD Risk Reduction
Primary Audience: This activity is targeted to any primary care provider who treats patients with CV and atherothrombotic risk factors
Launch Date: 19-Aug-10
Credits: 0.5 AMA PRA Category 1 Credit™
Expiration Date: The accreditation for this activity has expired.
Curriculum Name: Treatment Strategies, Risks and Complexities of a Patient with ACS

Learning Objectives

Upon completion of the activity, participants should be able to:

  1. Identify traditional and emerging risk factors that may aid in identifying patients at risk and with subclinical CVD

    Faculty

    David S. Kountz, MD, MBA, FACP
    Associate Professor of Medicine
    Robert Wood Johnson Medical School
    Attending Physician
    Jersey Shore University Medical Center
    New Brunswick, NJ     F. Wilford Germino, MD, FAHA
    Associate Professor, Department of Internal Medicine
    Rush Medical College
    Chicago, IL     Lawrence E. Mieczkowski, MD
    Medical Director
    The Center for Cardiometabolic Treatment & Education
    Clinical Associate Professor of Medicine
    Wright State University School of Medicine
    Dayton, OH     Marianne F. Smith
    Independent Medical Education Consultant and Medical Writer
    Hilton Head, SC
    To Obtain CME Credits
    • Read the learning objectives and faculty disclosures
    • Participate in the activity
    • Complete the post-test and activity evaluation
    • Physicians who successfully complete the post-test and evaluation will receive CME credit
    • All other participants who successfully complete the post-test and evaluation will receive a certificate of participation
    • You must score with a 70% or higher on the post-test to receive credit for this activity. You are provided with a second opportunity to retake the post-test if you do not achieve a passing score the first time

    Program Overview
    Rates of death from cardiovascular and cerebrovascular diseases have been steadily declining over the past few decades. In spite of these declines, atherothrombotic disease continues to be a world-wide challenge in terms of morbidity, premature death, and disability with tremendous costs to patients, healthcare systems, and society. CVD claims more lives each year than cancer, CLRD and accidents combined. In the United States alone, CVD and stroke remain the number 1 and number 3 killers of both men and women of all races and ethnicity. Nearly 2,300 Americans die of CVD each day, an average of 1 death every 38 seconds. 

    The primary care clinician plays a critical role in early diagnosis and detection of atherothrombosis, since the earliest signs and symptoms are often subtle and appear many years before its full-blown manifestation. Both primary and secondary prevention strategies include long term risk factor modification. For either primary or secondary prevention to be effective, provider/patient communication leading to good adherence to medication and lifestyle modifications is absolutely essential.

    Atherothrombosis and the heightened risk of recurrence represent major challenges to the clinician. Although vascular specialists often treat these patients acutely, the primary care setting is crucial in continuing lifestyle changes, effective drug therapy, and implementing treatment guidelines that have been initiated. Therefore, the primary care clinician must be comfortable and conversant with all current recommendations and guidelines, understand the most effective implementation techniques to use with their patients, and be familiar with resources available to assist in tackling this epidemic of CVD in their practices.

    This activity will demonstrate both knowledge and implementation of comprehensive risk reduction strategies and the AHA/ACC/ASA Guidelines for treating patients with atherothrombotic disease, with an emphasis on antiplatelet therapies.
     
    Statement of Disclosure and Independence
    It is the policy of Primary Care Network (PCN) to ensure all its sponsored educational activities are planned, developed, and conducted in accordance with the ACCME's Essential Areas and Policies. In accordance with ACCME requirements, Primary Care Network has Conflict of Interest and Disclosure Policies that are designed to ensure that Primary Care Network sponsored educational activities are fair balanced, independent, evidence‐based, and based on scientific rigor.
     
    PCN's Resolution of Personal Conflicts of Interest (COI) Policy aims to ensure that all conflicts are resolved prior to the activity, content is developed and presented free of commercial bias, and is in the interest of promoting improvements or quality in healthcare. All individuals who are in a position to influence and/or control content of a Primary Care Network sponsored activity are required to disclose to the participants any real or apparent conflict of interest related to the activity. The educational content is also reviewed for independence and content validation by an independent external clinical reviewer and internal clinical reviewer. Independence is also monitored through the activity and overall program evaluation process.
     
    The opinions, ideas, recommendations, and perspectives expressed in this activity are those of the program authors and presenting faculty only and do not necessarily reflect the opinions, ideas, recommendations or perspectives of their affiliated institutions, PCN, Primary Care Education, Advisory Boards and Consultants, or the activity's commercial supporters.
     
    Dr. Kountz is a consultant for Novartis and NiCox.
    Dr. Germino is on the speaker's bureau for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, BristolMyers Squibb/Sanofi Pharmaceuticals Partnership, and Novo Nordisk.  He is on the advisory board for Bristol Myers Squibb, BristolMyers Squibb/Sanofi Pharmaceuticals Partnership, and Forest Labs.  Dr. Germino is also a consultant for Forest Labs.
    Dr. Mieczkowski is on the speaker's bureau for Abbott Labs, AstraZeneca, Bristol-Myers Squibb, Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership, Merck, and Pfizer.
    Ms. Smith declares that she has no relevant financial relationships to disclose.
     
    Unlabeled Use Declaration
    During their presentation(s), faculty may discuss an unlabeled use or an investigational use not approved for a commercial product. Each faculty member is required to disclose this information to the audience when referring to an unlabeled or investigational use.
     
    Review Committee Disclosure
    In accordance with PCN policy, all content is reviewed by external independent peer reviewers for balance, objectivity, and commercial bias. The peer reviewers, staff, and other individuals who control content have no relevant financial relationships to disclose.
     
    Accreditation/Designation Statement
    Primary Care Network is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
     
    Primary Care Network designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.


    Course Viewing Requirements
    PC
    Internet Explorer (v6 or greater), or Firefox
    MAC
    Safari

    Acknowledgements
    This activity is sponsored by Primary Care Education.



    Acknowledgment of Commercial Support
    This activity was developed through an educational grant from the Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership.

        

    If you have any questions regarding this activity, send an email to education@primarycarenet.org or call (800)769-7565.
     
    Copyright © 2010 by Primary Care Education. All rights reserved.